Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 11, 2012, Pages 1687-1699

  Green, Margaret L ^a,b   Leisenring, Wendy ^a,b   Stachel, Daniel ^c   Pergam, Steven A ^a,b   Sandmaier, Brenda M ^a,b   Wald, Anna ^a,b   Corey, Lawrence ^a,b   Boeckh, Michael ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Cytomegalovirus; Hematopoietic cell transplantation; PCR; Preemptive therapy

Indexed keywords

ACICLOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR;

ADULT; ARTICLE; BACTERIAL INFECTION; CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; FEMALE; GASTROINTESTINAL DISEASE; HEMATOPOIETIC CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOSIS; NEUTROPENIA; PNEUMONIA; POLYMERASE CHAIN REACTION; RISK FACTOR; VIRUS LOAD;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GASTROINTESTINAL TRACT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDNISONE; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84867508466     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.05.015     Document Type: Article

References (41)

1. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
2. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
3. Fraser G.A., Walker Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant 2004, 10:287-297. Canadian Blood and Marrow Transplant Group.
4. Pollack M., Heugel J., Xie H., et al. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011, 17:664-673.
5. Boeckh M., Gallez-Hawkins G.M., Myerson D., Zaia J.A., Bowden R.A. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997, 64:108-113.
6. Gimeno C., Solano C., Latorre J.C., et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol 2008, 46:3311-3318.
7. Boeckh M., Huang M., Ferrenberg J., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004, 42:1142-1148.
8. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
9. Gentile G., Picardi A., Capobianchi A., et al. A prospective study comparing quantitative cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. BMC Infect Dis 2006, 6:167.
10. Lilleri D., Baldanti F., Gatti M., et al. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients. J Med Virol 2004, 73:412-418.
11. Kalpoe J.S., Kroes A.C., de Jong M.D., et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004, 42:1498-1504.
12. Ikewaki J., Ohtsuka E., Kawano R., Ogata M., Kikuchi H., Nasu M. Real-time PCR assay compared to nested PCR and antigenemia assays for detecting cytomegalovirus reactivation in adult T-cell leukemia-lymphoma patients. J Clin Microbiol 2003, 41:4382-4387.
13. Gerna G., Lilleri D., Caldera D., Furione M., Zenone Bragotti L., Alessandrino E.P. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008, 41:873-879.
14. Lilleri D., Gerna G., Furione M., et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood 2007, 110:2757-2760.
15. Einsele H., Hebart H., Kauffmann-Schneider C., et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000, 25:757-763.
16. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355:2032-2036.
17. Milano F., Pergam S.A., Xie H., et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 2011, 118:5689-5696.
18. Boeckh M., Bowden R.A., Gooley T., Myerson D., Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. Blood 1999, 93:1781-1782.
19. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007, 110:3071-3077.
20. Sangiolo D., Storer B., Nash R., et al. Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. Biol Blood Marrow Transplant 2005, 11:521-529.
21. Marr K.A., Crippa F., Leisenring W., et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004, 103:1527-1533.
22. Nakamae H., Kirby K.A., Sandmaier B.M., et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:694-703.
23. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
24. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
25. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
26. Chien J.W., Boeckh M.J., Hansen J.A., Clark J.G. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008, 111:2462-2469.
27. Nakamae H., Storer B., Sandmaier B.M., et al. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011, 96:1838-1845.
28. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
29. Piñana J.L., Martino R., Barba P., et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010, 45:534-542.
30. Marty F.M., Ljungman P., Papanicolaou G.A., et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011, 11:284-292.
31. George B., Pati N., Gilroy N., et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010, 12:322-329.
32. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
33. Guthrie K.A., Yong M., Frieze D., Corey L., Fredricks D.N. The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:675-681.
34. Mikulska M., Del Bono V., Raiola A.M., et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant 2009, 15:47-53.
35. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
36. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:273-282.
37. Mengelle C., Mansuy J.M., Da Silva I., Davrinche C., Izopet J. Comparison of 2 highly automated nucleic acid extraction systems for quantitation of human cytomegalovirus in whole blood. Diagn Microbiol Infect Dis 2011, 69:161-166.
38. Bravo D., Clari M.Á., Costa E., et al. Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. J Clin Microbiol 2011, 49:2899-2904.
39. Pang X.L., Fox J.D., Fenton J.M., et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9:258-268.
40. Griffiths P.D., Stanton A., McCarrell E., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
41. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.